

Caroline F Samer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1522444/publications.pdf>

Version: 2024-02-01

93
papers

2,766
citations

201674

27
h-index

189892

50
g-index

99
all docs

99
docs citations

99
times ranked

3612
citing authors

#	ARTICLE	IF	CITATIONS
1	Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19. <i>European Journal of Hospital Pharmacy</i> , 2023, 30, 113-116.	1.1	6
2	Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 30-43.	2.5	7
3	Hydromorphone Prescription for Pain in Children—What Place in Clinical Practice?. <i>Frontiers in Pediatrics</i> , 2022, 10, 842454.	1.9	4
4	Dexamethasone exposure in normal-weight and obese hospitalized COVID-19 patients: An observational exploratory trial. <i>Clinical and Translational Science</i> , 2022, 15, 1796-1804.	3.1	6
5	Mixing Drugs and Genetics: A Complex Hemorrhagic Cocktail. <i>American Journal of Medicine</i> , 2021, 134, e211-e212.	1.5	3
6	Cyber harassment of female scientists will not be the new norm. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 457-458.	9.1	4
7	Impact of Acute Inflammation on Cytochromes P450 Activity Assessed by the Geneva Cocktail. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1668-1676.	4.7	42
8	Impact of computerised physician order entry (CPOE) on the incidence of chemotherapy-related medication errors: a systematic review. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1123-1131.	1.9	8
9	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>CYP2D6</i> , <i>OPRM1</i> , and <i>COMT</i> Genotypes and Select Opioid Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 888-896.	4.7	212
10	Drug-Drug Interactions Leading to Adverse Drug Reactions with Rivaroxaban: A Systematic Review of the Literature and Analysis of VigiBase. <i>Journal of Personalized Medicine</i> , 2021, 11, 250.	2.5	9
11	Development and Preliminary Validation of LoAD Calc, a Mobile App for Calculating the Maximum Safe Single Dose of Local Anesthetics. <i>Healthcare (Switzerland)</i> , 2021, 9, 799.	2.0	4
12	Impact of Inflammation on Cytochromes P450 Activity in Pediatrics: A Systematic Review. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1537-1555.	3.5	11
13	CYP450 Genotype—Phenotype Concordance Using the Geneva Micrococktail in a Clinical Setting. <i>Frontiers in Pharmacology</i> , 2021, 12, 730637.	3.5	10
14	Drug-Drug Interactions with Direct Oral Anticoagulants: Practical Recommendations for Clinicians. <i>American Journal of Medicine</i> , 2021, 134, 939-942.	1.5	13
15	Case Report: Low Hematocrit Leading to Tacrolimus Toxicity. <i>Frontiers in Pharmacology</i> , 2021, 12, 717148.	3.5	5
16	Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. <i>BMJ</i> , The, 2021, 374, n2040.	6.0	54
17	Impact of SARS-CoV-2 Infection (COVID-19) on Cytochromes P450 Activity Assessed by the Geneva Cocktail. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1358-1367.	4.7	36
18	Live vaccines and immunosuppressive monoclonal antibodies: weighing up the benefit—risk assessment for natalizumab. <i>Journal of Travel Medicine</i> , 2021, 28, .	3.0	4

#	ARTICLE	IF	CITATIONS
19	Reviewing Data Integrated for PBPK Model Development to Predict Metabolic Drug-Drug Interactions: Shifting Perspectives and Emerging Trends. <i>Frontiers in Pharmacology</i> , 2021, 12, 708299.	3.5	24
20	Influence of Inflammation on Cytochromes P450 Activity in Adults: A Systematic Review of the Literature. <i>Frontiers in Pharmacology</i> , 2021, 12, 733935.	3.5	36
21	Editorial: Precision Medicine: Impact of Cytochromes P450 and Transporters Genetic Polymorphisms, Drug-Drug Interactions, Disease on Safety and Efficacy of Drugs. <i>Frontiers in Pharmacology</i> , 2021, 12, 834717.	3.5	1
22	Toward precision medicine in pediatric population using cytochrome P450 phenotyping approaches and physiologically based pharmacokinetic modeling. <i>Pediatric Research</i> , 2020, 87, 441-449.	2.3	13
23	Cytochrome P450 1A2 activity and incidence of thyroid disease and cancer after chronic or acute exposure to dioxins. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 296-303.	2.5	3
24	Vitamin D and Glaucoma: A Critical Review of the Literature. <i>Journal of Ophthalmology</i> , 2020, 2020, 1-8.	1.3	2
25	Evaluation of Phenotypic and Genotypic Variations of Drug Metabolising Enzymes and Transporters in Chronic Pain Patients Facing Adverse Drug Reactions or Non-Response to Analgesics: A Retrospective Study. <i>Journal of Personalized Medicine</i> , 2020, 10, 198.	2.5	10
26	Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00647.	2.4	21
27	The Swiss Cheese Prescribing Model for Precision Medicine. <i>American Journal of Medicine</i> , 2020, 133, 1249-1251.	1.5	3
28	Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs. <i>Swiss Medical Weekly</i> , 2020, 150, w20446.	1.6	21
29	Prescription de tramadol chez les enfants : une bonne alternative à la codéine ? <i>Douleur Et Analgesie</i> , 2020, 33, 247-256.	0.1	0
30	Automatic Classification of Discharge Letters to Detect Adverse Drug Reactions. <i>Studies in Health Technology and Informatics</i> , 2020, 270, 48-52.	0.3	3
31	Citizens' Participation in Health and Scientific Research in Switzerland. <i>Studies in Health Technology and Informatics</i> , 2020, 270, 1098-1102.	0.3	0
32	Old problem, new solutions: biomarker discovery for acetaminophen liver toxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 659-669.	3.3	12
33	Preclinical Evaluation of Safety of Fucoidan Extracts From <i>Undaria pinnatifida</i> and <i>Fucus vesiculosus</i> for Use in Cancer Treatment. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541987632.	2.0	4
34	Interaction between Fexofenadine and CYP Phenotyping Probe Drugs in Geneva Cocktail. <i>Journal of Personalized Medicine</i> , 2019, 9, 45.	2.5	6
35	The European Association for Clinical Pharmacology and Therapeutics' 25 th years™ young and going strong. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 743-750.	1.9	11
36	Safety Issues of Pharmacological Acute Pain Treatment in Children. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1130-1138.	4.7	7

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. <i>Pharmacogenomics Journal</i> , 2019, 19, 211-218.	2.0	25
38	Formation des médecins et infirmières à l'utilisation des opiacés par un jeu sérieux. <i>Douleur Et Analgesie</i> , 2019, 32, 54-60.	0.1	0
39	Complex Drug-Drug-Genetic-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1267-1293.	3.5	36
40	Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1347-1354.	3.5	52
41	When the Safe Alternative Is Not That Safe: Tramadol Prescribing in Children. <i>Frontiers in Pharmacology</i> , 2018, 9, 148.	3.5	34
42	Prevention of potentially inappropriate medication in internal medicine patients: A prospective study using the electronic application PIM-Check. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 860-866.	1.5	14
43	Absorption des médicaments lors de syndrome du grêle court. <i>Nutrition Clinique Et Metabolisme</i> , 2018, 32, 143-149.	0.5	1
44	Severe and persistent morphine-induced respiratory depression associated with ATP-Binding Cassette Subfamily B Member 1 and catechol-O-methyltransferase genetic defects. <i>European Journal of Anaesthesiology</i> , 2018, 35, 540-542.	1.7	2
45	Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2241-2248.	6.1	171
46	PIM-Check: development of an international prescription-screening checklist designed by a Delphi method for internal medicine patients. <i>BMJ Open</i> , 2017, 7, e016070.	1.9	30
47	Screening for genotypic and phenotypic variations in CYP450 activity in patients with therapeutic problems in a psychiatric setting, a retrospective study. <i>Pharmacological Research</i> , 2017, 118, 104-110.	7.1	13
48	Characterization of oxycodone in vitro metabolism by human cytochromes P450 and UDP-glucuronosyltransferases. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 144, 129-137.	2.8	23
49	Creation of the Swiss group of Pharmacogenomics and personalised Therapy (SPT). <i>Drug Metabolism and Personalized Therapy</i> , 2017, 32, 173-174.	0.6	1
50	Late Withdrawal Syndrome after Carbamazepine In Utero Exposure in a CYP2C9 Slow Metabolizer Newborn. <i>Frontiers in Pharmacology</i> , 2017, 8, 217.	3.5	2
51	Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect. <i>Frontiers in Pharmacology</i> , 2016, 7, 494.	3.5	45
52	Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 295-304.	4.7	36
53	Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 119, 284-290.	2.5	43
54	Letter by Bouatou et al Regarding Article, Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2016, 134, e3-4.	1.6	2

#	ARTICLE	IF	CITATIONS
55	HIV-Positive-to-HIV-Positive Liver Transplantation. American Journal of Transplantation, 2016, 16, 2473-2478.	4.7	40
56	In-vitro evaluation of DDI with cobicistat and ritonavir using heparg cell line. Clinical Therapeutics, 2015, 37, e98.	2.5	0
57	Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and review. New Microbes and New Infections, 2015, 6, 1-4.	1.6	4
58	Providing Quality Therapeutics in Switzerland: Role of the Stakeholders and Recent Incentives for Further Improvements. Clinical Therapeutics, 2015, 37, 1588-1592.	2.5	1
59	Screening for phenotypical variation in CYP activity in patients with therapeutic problem in psychiatric settings. Clinical Therapeutics, 2015, 37, e41-e42.	2.5	0
60	Evaluation of CYP450 and transporters expression and activity in heparg cell line under different conditions. Clinical Therapeutics, 2015, 37, e98.	2.5	0
61	Innovative approach to Blood sampling using dried Blood spots. application to Pharmacokinetics and Cytochrome P450 Phenotyping. Clinical Therapeutics, 2015, 37, e101.	2.5	0
62	Drug-related problems identification in general internal medicine: The impact and role of the clinical pharmacist and pharmacologist. European Journal of Internal Medicine, 2015, 26, 399-406.	2.2	59
63	Evidence-Based Choice of P2Y12 Inhibitors in End Stage Renal Disease Patients: A Mini-Review. Current Drug Metabolism, 2015, 16, 97-104.	1.2	5
64	Direct oral anticoagulants: efficacy and safety in patient subgroups. Swiss Medical Weekly, 2015, 145, w14081.	1.6	13
65	Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study. Clinical Pharmacokinetics, 2014, 53, 261-269.	3.5	23
66	Geneva Cocktail for Cytochrome P450 and P-Glycoprotein Activity Assessment Using Dried Blood Spots. Clinical Pharmacology and Therapeutics, 2014, 96, 349-359.	4.7	112
67	Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity. AIDS Research and Therapy, 2014, 11, 25.	1.7	13
68	Human urinary biomarkers of dioxin exposure: Analysis by metabolomics and biologically driven data dimensionality reduction. Toxicology Letters, 2014, 230, 234-243.	0.8	51
69	Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma. Bioanalysis, 2014, 6, 151-164.	1.5	46
70	Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-8.	2.5	16
71	Prediction by Pharmacogenetics of Safety and Efficacy of Non-Steroidal Anti-Inflammatory Drugs: A Review. Current Drug Metabolism, 2014, 15, 326-343.	1.2	39
72	Carbimazole-Induced, ANCA-Associated, Crescentic Glomerulonephritis: Case Report and Literature Review. Renal Failure, 2013, 35, 414-417.	2.1	10

#	ARTICLE	IF	CITATIONS
73	Influence des polymorphismes génétiques sur la variabilité de la réponse aux opioïdes. Douleur Et Analgesie, 2013, 26, 203-208.	0.1	4
74	Pharmacogénétique des anti-inflammatoires non stéroïdiens. Douleur Et Analgesie, 2013, 26, 195-202.	0.1	1
75	Pharmacokinetic Interaction Between Prasugrel and Ritonavir in Healthy Volunteers. Basic and Clinical Pharmacology and Toxicology, 2013, 112, 132-137.	2.5	43
76	Applications of CYP450 Testing in the Clinical Setting. Molecular Diagnosis and Therapy, 2013, 17, 165-184.	3.8	296
77	Hepatic fat loss in advanced nonalcoholic steatohepatitis: Are alterations in serum adiponectin the cause?. Hepatology, 2013, 57, 2180-2188.	7.3	136
78	Pulmonary embolism and iatrogenic Cushing's syndrome after co-administration of injected-triamcinolone and ritonavir. Aids, 2013, 27, 2827-2828.	2.2	9
79	Clinical Course and Management of Iatrogenic Cushing's Syndrome after Co-Administration of Injected-Triamcinolone and Ritonavir: a Systematic Review. Journal of Antivirals & Antiretrovirals, 2013, 05, .	0.1	2
80	Oral Flurbiprofen Metabolic Ratio Assessment Using a Single-Point Dried Blood Spot. Clinical Pharmacology and Therapeutics, 2012, 91, 489-496.	4.7	27
81	Serotonin syndrome following drug-drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patient. Aids, 2012, 26, 2417-2418.	2.2	20
82	Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treatment Reviews, 2011, 37, 251-260.	7.7	98
83	How close are we to individual analgesic adjustment according to a patient's genotype?. Personalized Medicine, 2011, 8, 289-292.	1.5	0
84	Automated system for on-line desorption of dried blood spots applied to LC/MS/MS pharmacokinetic study of flurbiprofen and its metabolite. Journal of Pharmaceutical and Biomedical Analysis, 2011, 54, 359-367.	2.8	73
85	Impact of Genetic Polymorphisms and Drug-Drug Interactions on Clopidogrel and Prasugrel Response Variability. Current Drug Metabolism, 2010, 11, 667-677.	1.2	49
86	The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. British Journal of Pharmacology, 2010, 160, 907-918.	5.4	141
87	Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. British Journal of Pharmacology, 2010, 160, 919-930.	5.4	156
88	Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics, 2008, 9, 905-933.	1.3	91
89	Pivotal role of CYP2D6 and CYP3A4 pathways on the antinociceptive effects of oxycodone. Clinical Pharmacology and Therapeutics, 2006, 79, P57-P57.	4.7	4
90	Individualizing analgesic prescription. Part II: pharmacogenetics of anti-inflammatory analgesics and co-analgesics. Personalized Medicine, 2006, 3, 271-297.	1.5	4

#	ARTICLE	IF	CITATIONS
91	Individualizing analgesic prescription Part I: pharmacogenetics of opioid analgesics. Personalized Medicine, 2006, 3, 239-269.	1.5	10
92	Analg�sie, l'importance du polymorphisme g�n�tique du cytochrome P450 2D6 dans l'individualisation th�rapeutique. Douleur Et Analgesie, 2004, 17, 63-66.	0.1	0
93	Development and validation of LoAD Calc, a mobile app for calculating the maximum safe single dose of local anesthetics (Preprint). JMIR Formative Research, 0, , .	1.4	0